Janssen Stops Development on Hepatitis C Drug

Article

A bloated hepatitis C drug marketplace causes manufacturer to focus on hepatitis B.

Janssen Sciences Ireland UC is discontinuing further development of its investigational hepatitis C virus (HCV) combination therapy JNJ-4178, due to an already bloated HCV marketplace, according to Reuters.

The manufacturer stated it would complete its ongoing phase 2 studies of JNJ-4178, but there will be no additional development thereafter, according to Reuters.

Janssen will instead focus its research and development efforts on a cure for chronic hepatitis B virus.

“Going forward, our hepatitis R&D efforts will focus on chronic hepatitis B, where a high unmet medical need still exists,” Lawrence Blatt, head of infectious disease at Janssen, told Endpoints News. “Our scientists are energized by this challenge and our research ambition is to achieve a functional cure of hepatitis B which affects over a quarter of a billion people globally.

“At Janssen, we focus our research and development on areas of greatest unmet medical need where we can combine our excellent internal science with the best available external innovation to bring optimized solutions and maximum benefit to patients.”

A few years ago, Janssen co-developed the first-in-class protease inhibitor telaprevir used in combination therapy to treat chronic HCV. The second-generation protease inhibitor Olysio was launched later and is approved in several countries, according to Reuters.

Related Videos
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
pharmacy | Image Credit: Diego Cervo - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.